People involved in the ongoing Phase III program for AstraZeneca’s (LSE: AZN) COVID-19 vaccine candidate say it produces a robust immune response in the elderly.
Talking to Reuters, a spokesperson for the company said: “It is encouraging to see immunogenicity responses were similar between older and younger adults and that reactogenicity was lower in older adults, where the COVID-19 disease severity is higher.”
If borne out by the data, the claim could be significant for the coronavirus frontrunner, given that older people are at a much greater risk of hospitalization or death from the novel coronavirus.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze